Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

ABSTRACT:

Background

Genotyping of melanomas is used to identify patients for treatment with BRAF and MEK inhibitors, but clinical responses are highly variable. This study investigated the utility of protein expression phenotyping to provide an integrated assessment of gene expression programs in BRAF/NRAS melanoma which would be useful for prognosis and may predict response to MEK inhibition.

Methods

Mass spectrometry profiling of early passage cell lines established from Stage III cutaneous melanomas was conducted. Basal protein expression was correlated with in vitro response to the MEK inhibitor, selumetinib. Protein expression in a cohort of 32 drug naïve BRAF/NRAS metastatic melanoma specimens was examined. The prognostic utility of a subset of these proteins and mRNA transcrip

SUBMITTER: Krisp C 

PROVIDER: S-EPMC6173697 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature